AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8392957
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ribavirin and interferon beta
Trial: 27198539
Drug: Contralateral natural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contralateral natural antagonists (control teeth)
Trial: 24469600
Drug: Amisulpride (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amisulpride (50 mg) with Korean traditional food
Trial: 24469600
Drug: Amisulpride (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amisulpride (50 mg) under fasting state
Trial: 22241786
Drug: Oral clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clarithromycin 500 mg/bid for 2 weeks and then 250 mg/d for 6 weeks
Trial: 22241786
Drug: Topical mometasone
RxNorm normalized name: mometasone Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical mometasone furoate 200 mcg/d for 8 weeks added to clarithromycin regimen
Trial: 3653498
Drug: Nicardipine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (30 mg three times a day)
Trial: 22399275
Drug: 0.8 g
RxNorm normalized name: Alcohol 0.8 g in 1 mL TOPICAL LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 g CMC-001
Trial: 22399275
Drug: 0.4 g
RxNorm normalized name: psyllium 0.4 GM Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 g CMC-001
Trial: 22399275
Drug: 0.2 g
RxNorm normalized name: methionine 0.2 gram ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 g CMC-001
Trial: 30184133
Drug: Scopolamine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine (4 μg/kg)
Trial: 11475269
Drug: Repaglinide 0.5
RxNorm normalized name: repaglinide 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repaglinide 0.5 mg
Trial: 12520624
Drug: Repaglinide 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repaglinide 1.0 mg
Trial: 12520624
Drug: Repaglinide 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repaglinide 2.0 mg
Trial: 25863562
Drug: High-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oral vitamin D3 (four doses of 2.5 mg at weeks 0, 2, 4, and 6)
Trial: 25863562
Drug: High-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oral vitamin D3
Trial: 25863562
Drug: High-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oral vitamin D3 and Placebo
Trial: 24618443
Drug: Oral pancreatic
RxNorm normalized name: pancreatin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral pancreatic enzyme supplementation
Trial: 9585778
Drug: Dopamine 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine 2.5 mcg/kg beginning 1 hour before arteriography and continuing for 12 hours
Trial: 11534531
Drug: β-blockade therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-blockade therapy
Trial: 514499
Drug: Amipaque 280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amipaque 280 mg I/ml
Trial: 662085
Drug: Isopaque Cerebral
RxNorm normalized name: Sus scrofa cerebral cortex preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isopaque Cerebral 280 mg I/ml
Trial: 662085
Drug: Amipaque 280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amipaque 280 mg I/ml (selective external carotid injection)
Trial: 662085
Drug: Isopaque (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isopaque (selective external carotid injection)
Trial: 29072432
Drug: 7-day moxifloxacin-dexlansoprazole
RxNorm normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7-day moxifloxacin-dexlansoprazole based triple therapy with probiotic
Trial: 29072432
Drug: 14-day moxifloxacin-dexlansoprazole
RxNorm normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 14-day moxifloxacin-dexlansoprazole based triple therapy with probiotic
Trial: 29072432
Drug: 7-day moxifloxacin-dexlansoprazole
RxNorm normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7-day moxifloxacin-dexlansoprazole based triple therapy with placebo
Trial: 29072432
Drug: 14-day moxifloxacin-dexlansoprazole
RxNorm normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 14-day moxifloxacin-dexlansoprazole based triple therapy with placebo
Trial: 22136848
Drug: TSH suppressive
RxNorm normalized name: TSH-releasing hormone
DrugBank: Protirelin (DB09421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TSH suppressive therapy (group A)
Trial: 22136848
Drug: No therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No therapy (group B)
Trial: 16443858
Drug: nateglinide 30
RxNorm normalized name: nateglinide 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nateglinide 30 mg
Trial: 16443858
Drug: glibenclamide 1.25
RxNorm normalized name: glibenclamide 1.25 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glibenclamide 1.25 mg
Trial: 11029017
Drug: Aspirin (325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (325 mg with each meal, three times per day for 2.5 days)
Trial: 9071623
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg single dose of ketoconazole (Regimen A)
Trial: 9071623
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg daily dose of ketoconazole for 10 days (Regimen B)
Trial: 7871052
Drug: Arecoline (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arecoline (low dose intravenous infusion for up to 2 weeks)
Trial: 7871052
Drug: Arecoline (blinded,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arecoline (blinded, placebo-controlled, individualized optimal dosing for 5 days)
Trial: 3518547
Drug: Naftidrofuryl (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naftidrofuryl (3 X 200 mg tablets daily with meals)
Trial: 3518547
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 tablets daily)
Trial: 30206267
Drug: 2-g oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-g oral TXA 2 hours preoperatively
Trial: 30206267
Drug: 20-mg/kg IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-mg/kg IV TXA 5 minutes prior to incision
Trial: 30206267
Drug: 2-g IA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-g IA TXA
Trial: 25666427
Drug: High-dose CDDP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose CDDP (810 mg)
Trial: 25666427
Drug: Mid-dose CDDP
RxNorm normalized name: CDDP
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mid-dose CDDP (540 mg)
Trial: 23434737
Drug: gD2-AS04 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gD2-AS04 vaccine formulations (20, 40, or 80 μg of truncated glycoprotein D from HSV-2 strain)
Trial: 23434737
Drug: gD2-AS04 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gD2-AS04 vaccine formulations (different aluminum salts: AlPO₄ or Al(OH)₃)
Trial: 23434737
Drug: gD2-AS04 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gD2-AS04 vaccine formulations (different preservatives)
Trial: 23434737
Drug: gD2-AS04 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gD2-AS04 vaccine formulations (different volumes: 0.5 or 1 ml)
Trial: 23434737
Drug: gD2-AS04 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gD2-AS04 vaccine formulations
Trial: 20350333
Drug: Bosentan 500
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bosentan 500 mg twice daily
Trial: 16624552
Drug: High-dose imatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose imatinib (800 mg daily)
Trial: 16624552
Drug: Imatinib (general
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib (general treatment)
Trial: 1532316
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg slow release oral isradipine
Trial: 2944997
Drug: Etodolac 200
RxNorm normalized name: etodolac 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etodolac 200 mg
Trial: 6212554
Drug: Etodolac 100
RxNorm normalized name: etodolac 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etodolac 100 mg
Trial: 29259382
Drug: Tolvaptan (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolvaptan (7.5 mg)
Trial: 20552330
Drug: Lycopene capsules
RxNorm normalized name: lycopene Oral Capsule
DrugBank: Lycopene (DB11231)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lycopene capsules
Trial: 20552330
Drug: Lycopene supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lycopene supplementation (combined juice and capsules)
Trial: 19567023
Drug: Chai Shao
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chai Shao Liu Jun Tang in combination with Lamivudine
Trial: 17878255
Drug: Leptin levels
RxNorm normalized name: leptin
DrugBank: Leptin (DB05098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leptin levels in women (12.5 ng/ml)
Trial: 17878255
Drug: C-reactive protein
RxNorm normalized name: C-reactive protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-reactive protein (CRP) levels in women (0.75 mg/liter)
Trial: 17878255
Drug: Mendelian randomization
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mendelian randomization test for CRP as a causal agent for leptin
Trial: 12402413
Drug: Maternal antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal antibodies anti-Ro/SSA and anti-La/SSB
Trial: 11738121
Drug: Antiretroviral treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral treatments
Trial: 2456174
Drug: Iloprost at
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iloprost at a dose of 2 ng/kg/min for 6 hours daily for 6 days
Trial: 2456174
Drug: Iloprost at
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iloprost at a dose of 1 ng/kg/min for 6 hours daily for 6 days
Trial: 24973862
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg omega‐3 fatty acid supplements (n = 28)
Trial: 20868638
Drug: EGb-761, 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGb-761, 240 mg/d
Trial: 19246729
Drug: nelfinavir 1250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nelfinavir 1250 mg every 12 hours on days 1-4
Trial: 19246729
Drug: nelfinavir 1250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nelfinavir 1250 mg every 12 hours on days 1-3 plus 3125 mg on day 4
Trial: 19246729
Drug: moxifloxacin 400
RxNorm normalized name: moxifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: moxifloxacin 400 mg every 24 hours on days 1-4
Trial: 15749042
Drug: Azithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (500 mg daily for 3 days)
Trial: 16618915
Drug: Telithromycin (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telithromycin (800 mg daily for 5 days)
Trial: 15585764
Drug: Cystine intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cystine intake of 5 mg.kg(‐1).d(‐1)
Trial: 15585764
Drug: Cystine intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cystine intake of 12 mg.kg(‐1).d(‐1)
Trial: 15585764
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg cystine intake (previously estimated)
Trial: 9480466
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose methotrexate (7.5-15 mg weekly)
Trial: 8492409
Drug: Regimen A
RxNorm normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen A (intermediate dose cytosine arabinoside (Ara‐C), cyclophosphamide (CPM) plus 6MP)
Trial: 8492409
Drug: Regimen B
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen B (high-dose Ara‐C plus CPM)
Trial: 31818531
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g of refined cold-pressed flaxseed oil providing 4.7 g ALA (n = 29)
Trial: 31818531
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g of high-oleic sunflower oil (control) (n = 30)
Trial: 29019418
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care plus daily motivational interviewing-based text messages
Trial: 28961714
Drug: Intravenous posaconazole
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous posaconazole 300 mg twice daily on day 1, followed by 300 mg once daily for 4-28 days, then oral posaconazole 400 mg twice daily or 200 mg three times daily for 28 days.
Trial: 26290323
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment with concentrated blood and bone marrow aspirate (cB + cBMA)
Trial: 26290323
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment without cB + cBMA (sham treatment)
Trial: 23406601
Drug: Intranasal fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal fluticasone furoate (FF) and intraocular placebo (PL)
Trial: 23406601
Drug: Intranasal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal placebo (PL) and intraocular olopatadine (OLO)
Trial: 23406601
Drug: Intranasal fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal fluticasone furoate (FF) and intraocular olopatadine (OLO)
Trial: 23406601
Drug: Intranasal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal placebo (PL) and intraocular placebo (PL)
Trial: 23406601
Drug: Intranasal fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal fluticasone furoate (FF)
Trial: 18001177
Drug: Antithyroid drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithyroid drugs (ATDs) therapy in Graves' disease
Trial: 18001177
Drug: Antithyroid drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithyroid drugs (ATDs) therapy in painless thyroiditis
Trial: 15256294
Drug: Massage therapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage therapy (30-min massages three times per week for 5 weeks)
Trial: 9416722
Drug: Rocuronium 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 1.2 mg/kg (three times the ED95)
Trial: 9416722
Drug: Succinylcholine 2
RxNorm normalized name: succinylcholine 20 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine 2 mg/kg
Trial: 8236504
Drug: RT plus
RxNorm normalized name: Recort Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT plus NTX (100 mg every other day)
Trial: 26272704
Drug: Single-visit treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-visit treatment
Trial: 26272704
Drug: Multiple-visit treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-visit treatment
Trial: 21290248
Drug: Racemic cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racemic cyclophosphamide (CYC) 900 or 1,000 mg/m²
Trial: 19717250
Drug: Contingency management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contingency management with clinic-delivered, abstinence-based incentive program and weekly behavioral parent training sessions
Trial: 19717250
Drug: Attendance-based incentive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attendance-based incentive program and weekly psychoeducational parent sessions (Control)
Trial: 19717250
Drug: Both conditions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both conditions (MET/CBT and drug-testing program)
Trial: 17704421
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus surgery (preoperative cisplatin plus fluorouracil)
Trial: 17704421
Drug: Objective tumor
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Objective tumor regression after preoperative chemotherapy
Trial: 2442415
Drug: Sodium pentosanpolysulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium pentosanpolysulfate (200 mg twice daily)
Trial: 31937532
Drug: Morning warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning warfarin ingestion
Trial: 31937532
Drug: Evening warfarin
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evening warfarin ingestion
Trial: 31037289
Drug: Aflibercept (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aflibercept (2.0 mg intravitreous injection, n = 226)
Trial: 23575197
Drug: Telaprevir (TVR)
RxNorm normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Telaprevir (TVR) treatment
Trial: 19803620
Drug: Family intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Family intervention to improve medication adherence and reduce relapse
Trial: 17103307
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g L-Arg
Trial: 17103307
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g L-Arg
Trial: 14523338
Drug: 0.05% GTN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% GTN ointment
Trial: 14523338
Drug: 0.1% GTN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% GTN ointment
Trial: 1559321
Drug: Disopyramide (D.RET.)
DrugBank: Disopyramide (DB00280)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Disopyramide (D.RET.) 250 mg twice daily
Trial: 1559321
Drug: Amiodarone 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone 1200 mg daily for 10 days, then 200 mg daily
Trial: 4014620
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg controlled-release oral morphine
Trial: 4014620
Drug: 90 mg
RxNorm normalized name: papain 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg controlled-release oral morphine
Trial: 4014620
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg intramuscular morphine
Trial: 29739782
Drug: Digital self‐management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital self‐management intervention for blood pressure self‐monitoring and medication change
Trial: 12032741
Drug: Herbal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal treatment (90 mg ephedrine alkaloids and 192 mg caffeine per day)
Trial: 1467659
Drug: Local intravaginal
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local intravaginal application of metronidazole (500 mg)
Trial: 1467659
Drug: Single-shot prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-shot prophylaxis with cefuroxime (1,500 mg intravenously)
Trial: 6507770
Drug: Bupivacaine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine with initial peridural injection of 100 μg fentanyl
Trial: 30122200
Drug: Test product
RxNorm normalized name: Patch test product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test product containing hydrolyzed fish collagen, vitamins, antioxidants, and other active ingredients, taken daily for 90 days.
Trial: 11236211
Drug: Combination topical
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination topical gel (5% benzoyl peroxide and 1% clindamycin)
Trial: 7657446
Drug: 1% clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% clindamycin gel
Trial: 9428832
Drug: Metformin 500
RxNorm normalized name: metformin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 500 mg daily
Trial: 9428832
Drug: Metformin 1000
RxNorm normalized name: metformin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 1000 mg daily
Trial: 9428832
Drug: Metformin 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 1500 mg daily
Trial: 29659896
Drug: Metformin 2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 2000 mg daily
Trial: 9428832
Drug: Metformin 2500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 2500 mg daily
Trial: 3303439
Drug: Azathioprine and
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine and low-dose prednisolone (AP)
Trial: 2526721
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (MPA), 150 mg/day
Trial: 4602899
Drug: To‐336 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To‐336 vaccine
Trial: 4602899
Drug: HPV77. DE‐5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV77. DE‐5 vaccine